01323nas a2200409   4500000000100000000000100001000000100002008004100003653003100044653002800075653005600103653002500159653003500184653006900219653004000288653001100328653004300339653002400382653005700406653002600463653002200489653002200511653002000533100001300553700001300566700001500579700001200594700001500606700001200621700001500633700001400648700001500662245020100677250001500878490000600893020001400899       2022                            d10aAdministration, Inhalation10aAdrenal Cortex Hormones10aAdrenergic beta-2 Receptor Agonists/adverse effects10a*Asthma/drug therapy10aBeclomethasone/therapeutic use10aBudesonide, Formoterol Fumarate Drug Combination/therapeutic use10aFormoterol Fumarate/therapeutic use10aHumans10aMuscarinic Antagonists/therapeutic use10aPrimary health care10a*Pulmonary Disease, Chronic Obstructive/drug therapy10aRetrospective Studies10aCOPD epidemiology10aCOPD pharmacology10ainhaler devices1 aA. Czira1 aV. Banks1 aG. Requena1 aR. Wood1 aT. Tritton1 aR. Wild1 aC. Compton1 aM. Duarte1 aA. Ismaila00aCharacterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England  a2022/09/290 v9  a2052-4439